Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.71 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560749 | 0.83 | SCD (1.00) | SCDGPR119 | |
| SCHEMBL2557553 | 0.80 | SCD (0.69) | SCDGPR119 | |
| SCHEMBL2564030 | 0.80 | SCD (1.00) | SCDGPR119 | |
| SCHEMBL2558060 | 0.78 | SCD (1.00) | SCDGPR119 | |
| SCHEMBL2562375 | 0.77 | SCD (0.65) | SCDGPR119 | |
| SCHEMBL2561220 | 0.77 | SCD (0.65) | SCDGPR119 | |
| SCHEMBL2559005 | 0.77 | SCD (0.76) | SCDGPR119 | |
| SCHEMBL12287525 | 0.72 | SCD (1.00) | SCDGPR119 | |
| SCHEMBL2564089 | 0.71 | SCD (1.00) | SCDGPR119 | |
| SCHEMBL9902324 | 0.70 | SCD (0.56) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560963-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-02-27 | — | — | EP | claimed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | claimed |
| WO-2011131593-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-10-27 | — | — | WO | claimed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| EP-2560963-B1 | PYRAZINE DERIVATIVES AS INHIBITORS OF THE ENZYME SCD-1 FOR THE TREATMENT OF CANCER DISEASES AND DIABETES | PF MEDICAMENT (FR) | 2016-10-05 | — | — | EP | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962837-B2 | Nitrogen heterocycle derivatives, preparation thereof and application thereof in human therapeutics | PIERRE FABRE MEDICAMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2560963-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2011131593-A1 | DERIVATIVES OF NITROGEN HETEROCYCLES, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040928-A1 | NITROGEN HETEROCYCLE DERIVATIVES, PREPARATION THEREOF AND APPLICATION THEREOF IN HUMAN THERAPEUTICS | PRMT1, NNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SCD 4464/4885GPR119 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.